Latest Due Diligence News

Warriedar Resources has sent out the Scheme Booklet to shareholders detailing its proposed acquisition of Capricorn Metals, with the Board unanimously recommending approval. Key meetings and court dates are set as the company moves toward a significant corporate milestone.

Felix Gold Limited has been found in breach of ASX continuous disclosure rules after delaying the announcement of a U.S. federal site visit to its Alaska antimony project, prompting an internal review of its disclosure policies.

Summit Minerals Limited has announced a fully underwritten entitlement offer to raise approximately $1.08 million, aimed at advancing its Brazilian exploration projects and funding potential acquisitions. The offer, priced at $0.03 per share, is open to Australian and New Zealand shareholders and is expected to dilute non-participating shareholders by about 25%.

Invex Therapeutics has ended negotiations on two neurological asset acquisitions following due diligence setbacks and shareholder disputes, while advancing R&D collaborations and managing financial stability.

Impact Minerals has partnered with Kuniko Limited, granting them the right to earn up to 70% of the Commonwealth gold-silver project in NSW’s Lachlan Fold Belt through a $3 million exploration commitment over four years.

Evergreen Lithium has identified multiple compelling gold targets at its Mt Monger Gold Project, leveraging strong historic drilling and prime infrastructure to fast-track development plans.

Anatara Lifesciences has raised $1.2 million through a discounted share placement to fund its Anti-Obesity project and explore new opportunities. The capital injection reflects strong institutional support amid ongoing pipeline development.

St Barbara updates shareholders on its ongoing strategic review, highlighting stalled Atlantic separation talks and advancing Simberi sale discussions, while reaffirming commitment to a major expansion.

Quantum Graphite Ltd reported a significant revenue jump alongside a $4.9 million net loss for FY2025, as it pushes forward with its Uley 2 graphite project backed by major infrastructure and funding initiatives.

Invex Therapeutics has discontinued exclusive negotiations to acquire a rare neurological disease company due to board instability triggered by a shareholder requisition notice. Despite this setback, the company remains committed to diversifying its neurological treatment portfolio.

TT Investments, led by 360 Capital’s Executive Chairman Tony Pitt, has launched an unconditional off-market takeover bid for 360 Capital Group at an improved price of A$0.31 per security, signaling potential delisting and operational overhaul.

Burgundy Diamond Mines has been approved as eligible for up to CAD 150 million in emergency funding to sustain operations at its Ekati mine amid a sharp downturn in diamond prices caused by US tariffs. Trading in its securities remains suspended pending funding confirmation.